{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:20Z","timestamp":1760906960705},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ygyno.2010.10.011","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T12:49:23Z","timestamp":1289306963000},"page":"38-42","source":"Crossref","is-referenced-by-count":5,"title":["An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer"],"prefix":"10.1016","volume":"120","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Hartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Legenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.10.011_bb0005","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology\u2122. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. V.2.2010. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/ovarian.pdf. Accessed June 7, 2010."},{"key":"10.1016\/j.ygyno.2010.10.011_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0020","series-title":"SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988\u20132001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD","article-title":"Cancer of the ovary","author":"Kosary","year":"2007"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0025","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.2002.20.5.1158","article-title":"Is there a \u201cbest\u201d choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?","volume":"20","author":"Cannistra","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0030","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6\u201312months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0040","article-title":"Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4\/OVAR 2.2)","volume":"22","author":"Ledermann","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0045","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0050","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study","volume":"16","author":"Gonz\u00e1lez-Martin","year":"2005","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.ygyno.2010.10.011_bb0055","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2010.10.011_bb0060","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0065","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0075","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0090-8258(03)00470-0","article-title":"Weekly topotecan in the management of ovarian cancer","volume":"90","author":"Morris","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2005.07.020","article-title":"A phase I\/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma","volume":"99","author":"Rose","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.16518","article-title":"An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: first stage results","volume":"26","author":"Schwartz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.ygyno.2010.10.011_bb0090","article-title":"IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21days as second-line therapy in subjects with relapsed ovarian cancer (OC): dose selection for a phase II study","volume":"19","author":"Schwartz","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0095","series-title":"WHO handbook for reporting results of cancer treatment","year":"1979"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.5005","article-title":"Gemcitabine\/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG","volume":"22","author":"Pfisterer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ygyno.2010.10.011_bb0105","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/sim.4780110703","article-title":"Planned versus attained design in phase II clinical trials","volume":"11","author":"Green","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-8-3","article-title":"A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study","volume":"8","author":"Bafaloukos","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2004.10.011","article-title":"A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma","volume":"96","author":"Kose","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0120","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/IGC.0b013e3181a8b938","article-title":"Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer","volume":"19","author":"Rapoport","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0125","series-title":"Clinical trial endpoints for the approval of cancer drugs and biologics","year":"2007"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00280-007-0617-2","article-title":"Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I\/II study","volume":"62","author":"Koensgen","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0135","doi-asserted-by":"crossref","first-page":"497429","DOI":"10.1155\/2010\/497429","article-title":"Treatment of recurrent ovarian cancer\u2014at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.ygyno.2010.10.011_bb0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1576\/toag.9.4.265.27357","article-title":"Current practice and new developments in ovarian cancer chemotherapy","volume":"9","author":"Ali","year":"2007","journal-title":"Obstetrician Gynaecologist"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T04:30:59Z","timestamp":1559795459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810007560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0090825810007560"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.10.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}